Authors
Latest:
Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon CancerLead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.
Latest:
Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic OncologyThe expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon CancerArdaman Shergill, MD, and Aparna Raj Parikh, MD, explore ongoing clinical investigations evaluating the use of circulating tumor DNA in the treatment of early-stage colon cancer.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Thierry Facon, MD, Looks to the Future of Therapy for Multiple Myeloma at 2022 ASCOThierry Facon, MD, spoke about treatment combinations that have seen success in patients with multiple myeloma, as well as where future research should be focused.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
Latest:
De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical ConsiderationHow treatment paradigms regarding HPV-positive squamous cell carcinoma will evolve, particularly in the era of precision medicine, is a provocative question and is the subject of this review.
Latest:
Oncology Peer Review On-The-Go: Integrative Oncology in Young Population with Breast CancerYancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Future Directions in mHSPC Management: An Evolving Treatment LandscapeKey opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.
Latest:
Jorge Nieva, MD, Discusses the Impact of IMpower010 and New Trials in Progress for Early-Stage NSCLCCancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.
Latest:
Gennady Bratslavsky, MD, Reviews Emerging Research in RCCGennady Bratslavsky, MD, at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, spoke about which research in renal cell carcinoma has the greatest potential for clinical impact.
Latest:
Expert Commentary on the Product Profile of Amivantamab-vmjwIn an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Latest:
Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MMSpecialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and PhysiciansPractical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.
Latest:
Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for TransplantExperts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.
Latest:
Tony S. Mok, MD, Reviews Importance of Adjuvant Nivolumab in Resectable NSCLCTony S. Mok, MD, spoke about utilizing adjuvant or neoadjuvant treatment for patients with non–small cell lung cancer.
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
